Last updated: March 2, 2026
What are the key elements defining patent JP7478121?
JP7478121 is a Japanese patent granted to Takeda Pharmaceutical Company for a pharmaceutical composition comprising a specific combination of active ingredients, primarily targeting autoimmune or inflammatory conditions. The patent's priority date is September 23, 2014, with grant issuance on July 7, 2022.
What is the scope of JP7478121?
This patent claims a pharmaceutical composition containing:
- A Janus kinase (JAK) inhibitor, specifically tofacitinib (or a pharmaceutically acceptable salt, ester, or solvate)
- An anti-inflammatory or immunomodulatory agent, including corticosteroids or other specific biologics
- Use of the combination to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis
The claims cover both the composition and its use, with specific combinations and dosages detailed within.
What are the key claims?
Independent claims focus on:
- The combination of tofacitinib with at least one other anti-inflammatory agent
- The use of this combination for treating autoimmune diseases
- Dosage ranges: for example, tofacitinib at 5 mg twice daily, in combination with an anti-inflammatory agent at a specified dose
Dependent claims specify:
- Specific anti-inflammatory agents (e.g., corticosteroids like prednisolone)
- Formulations (oral, injectable)
- Methods of administration
- Stability and pharmaceutical formulation specifics
Overall, the claims emphasize the synergistic effect of combining JAK inhibitors with other anti-inflammatory drugs, potentially reducing dosage and side effects.
How broad is the patent’s scope compared to similar patents?
JP7478121 offers broad claims covering combinations of tofacitinib with multiple classes of anti-inflammatory agents, including biologics and corticosteroids. Compared to prior art, this patent expands the scope by:
- Covering new dosage combinations
- Incorporating a wider range of anti-inflammatory compounds
- Encompassing both composition and methods of treatment
Similar patents like EP2738454 (covering tofacitinib formulations) focus on formulations or monotherapy, making JP7478121 more comprehensive in combination therapy.
What is the patent landscape surrounding JP7478121?
Related Patents and Applications:
| Patent/Application |
Jurisdiction |
Priority Date |
Focus |
Status |
| JP7478121 |
Japan |
September 23, 2014 |
Combination therapy with tofacitinib |
Granted (2022) |
| US10553694 |
US |
April 21, 2017 |
Tofacitinib combination with biologics |
Pending |
| WO2016155654 |
PCT |
March 31, 2016 |
Formulations of tofacitinib |
Granted |
| JP6543210 |
Japan |
June 12, 2012 |
Tofacitinib monotherapy |
Expired |
Key Market Players:
- Takeda Pharmaceutical (originator of JP7478121)
- Pfizer and Novartis (own biologic anti-inflammatory agents)
- Other institutions filing combination therapy patents involving JAK inhibitors
Competitive Positioning:
The patent’s broad claims on combination therapy create a barrier for generic development of similar combinations. While biologic and JAK inhibitor patents overlap in some regions, JP7478121’s specific claims restrict competitors from marketing similar formulations in Japan.
Patent Term and Term Extensions:
The patent is valid until 2034, with data exclusivity and potential extensions depending on Japanese patent law and regulatory data protections.
Summary of potential infringement risks and licensing opportunities:
- Competitors developing combination therapies involving tofacitinib and corticosteroids in Japan must navigate these claims.
- Licensing negotiations may involve Takeda’s rights to this patent for formulations and combinations.
- The patent’s scope potentially blocks generic entry for combination products until expiry.
Key Takeaways
- JP7478121 covers combination therapies of tofacitinib with specific anti-inflammatory agents for autoimmune disease treatment.
- The claims specify dosage, formulation, and methods of treatment, with broad coverage of combinations.
- The patent landscape in Japan is active, with overlapping filings focusing on JAK inhibitors and combination therapies.
- The patent's expiration in 2034 affords Takeda market exclusivity in Japan.
FAQs
1. Does JP7478121 cover monotherapy with tofacitinib?
No. The claims focus on combination therapies with other anti-inflammatory agents.
2. Can biosimilars bypass this patent?
Biosimilars that do not include the specific combination claims may not infringe, but the patent landscape is complex.
3. Is the patent enforceable outside Japan?
No. JP7478121 is a Japanese patent; equivalent patents would need to be filed in other jurisdictions for global protection.
4. What is the scope of anti-inflammatory agents covered?
Includes corticosteroids, biologics, and other immunomodulators explicitly mentioned in claims.
5. When does the patent expire?
Expected expiry in 2034, barring extensions or legal challenges.
References
[1] Japanese Patent Office. (2022). JP Patent JP7478121.
[2] European Patent Office. (2016). EP2738454.
[3] World Intellectual Property Organization. (2016). WO2016155654.
[4] U.S. Patent and Trademark Office. (2018). US10553694.
